U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H25N3O3
Molecular Weight 367.4415
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SORAPRAZAN

SMILES

COCCO[C@H]1[C@H](O)[C@H](NC2=C1C=CN3C(C)=C(C)N=C23)C4=CC=CC=C4

InChI

InChIKey=PWILYDZRJORZDR-MISYRCLQSA-N
InChI=1S/C21H25N3O3/c1-13-14(2)24-10-9-16-18(21(24)22-13)23-17(15-7-5-4-6-8-15)19(25)20(16)27-12-11-26-3/h4-10,17,19-20,23,25H,11-12H2,1-3H3/t17-,19-,20-/m1/s1

HIDE SMILES / InChI
Soraprazan (remofuscin), a potassium-competitive acid blocker (P-CAB; formerly called an acid pump antagonist [APA]), is being developed by Katairo GmbH for the treatment of Stargardt's disease and dry age-related macular degeneration (AMD). Clinical development is underway for Stargardt's disease and dry age-related macular degeneration in the Netherlands and Germany. On 13 November 2013, orphan designation was granted by the European Commission to Katairo GmbH, Germany, for soraprazan for the treatment of Stargardt’s disease. Soraprazan is a a highly potent reversible, and fast-acting inhibitor of gastric H,K-ATPase. Soraprazan shows immediate inhibition of acid secretion in various in vitro models and in vivo and was found to be more than 2000-fold selective for H,K-ATPase over Na,K- and Ca-ATPases.

Approval Year

PubMed

PubMed

TitleDatePubMed
Soraprazan: setting new standards in inhibition of gastric acid secretion.
2007 Jun
Medicinal Attributes of Imidazo[1,2-a]pyridine Derivatives: An Update.
2016
Patents

Sample Use Guides

Soraprazan was administrated in oral application of 6, 12 and 24 mg/kg/day for 52 weeks in the Cynomolgus monkey.
Route of Administration: Oral
Soraprazan has an IC(50) of 0.1 uM if measured with ion leaky vesicles and of 0.19 uM in isolated gastric glands. With a K(i) of 6.4 nM, a K(d) of 26.4 nM, and a B(max) of 2.89 nmol/mg, this compound is a highly potent and reversible inhibitor of the H,K-ATPase.
Name Type Language
SORAPRAZAN
INN   WHO-DD  
INN  
Official Name English
Soraprazan [WHO-DD]
Common Name English
soraprazan [INN]
Common Name English
(7R,8R,9R)-7-(2-METHOXYETHOXY)-2,3-DIMETHYL-9-PHENYL-7,8,9,10-TETRAHYDROIMIDAZO(1,2-H)(1,7)NAPHTYRIDIN-8-OL
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29723
Created by admin on Sat Dec 16 17:19:37 GMT 2023 , Edited by admin on Sat Dec 16 17:19:37 GMT 2023
EU-Orphan Drug EU/3/13/1208
Created by admin on Sat Dec 16 17:19:37 GMT 2023 , Edited by admin on Sat Dec 16 17:19:37 GMT 2023
FDA ORPHAN DRUG 617617
Created by admin on Sat Dec 16 17:19:37 GMT 2023 , Edited by admin on Sat Dec 16 17:19:37 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C87388
Created by admin on Sat Dec 16 17:19:37 GMT 2023 , Edited by admin on Sat Dec 16 17:19:37 GMT 2023
PRIMARY
SMS_ID
100000089238
Created by admin on Sat Dec 16 17:19:37 GMT 2023 , Edited by admin on Sat Dec 16 17:19:37 GMT 2023
PRIMARY
PUBCHEM
213054
Created by admin on Sat Dec 16 17:19:37 GMT 2023 , Edited by admin on Sat Dec 16 17:19:37 GMT 2023
PRIMARY
EVMPD
SUB25228
Created by admin on Sat Dec 16 17:19:37 GMT 2023 , Edited by admin on Sat Dec 16 17:19:37 GMT 2023
PRIMARY
MESH
C521310
Created by admin on Sat Dec 16 17:19:37 GMT 2023 , Edited by admin on Sat Dec 16 17:19:37 GMT 2023
PRIMARY
ChEMBL
CHEMBL2105502
Created by admin on Sat Dec 16 17:19:37 GMT 2023 , Edited by admin on Sat Dec 16 17:19:37 GMT 2023
PRIMARY
CAS
261944-46-1
Created by admin on Sat Dec 16 17:19:37 GMT 2023 , Edited by admin on Sat Dec 16 17:19:37 GMT 2023
PRIMARY
FDA UNII
5XB3671655
Created by admin on Sat Dec 16 17:19:37 GMT 2023 , Edited by admin on Sat Dec 16 17:19:37 GMT 2023
PRIMARY
INN
8188
Created by admin on Sat Dec 16 17:19:37 GMT 2023 , Edited by admin on Sat Dec 16 17:19:37 GMT 2023
PRIMARY